Malignant Solid Tumors Clinical Trials

10 recruiting

Malignant Solid Tumors Trials at a Glance

19 actively recruiting trials for malignant solid tumors are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Houston, Shanghai, and Nashville. Lead sponsors running malignant solid tumors studies include Suzhou Suncadia Biopharmaceuticals Co., Ltd., Zhejiang University, and M.D. Anderson Cancer Center.

Browse malignant solid tumors trials by phase

Treatments under study

About Malignant Solid Tumors Clinical Trials

Looking for clinical trials for Malignant Solid Tumors? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1Phase 2

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc.428 enrolled7 locationsNCT07287995
Recruiting
Phase 1Phase 2

A Study of TAK-505 in Adults With Solid Tumors

Malignant Solid Tumors
Takeda151 enrolled15 locationsNCT07436728
Recruiting
Phase 1

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
West China Hospital6 enrolled2 locationsNCT07040943
Recruiting
Not Applicable

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.30 enrolled1 locationNCT06658951
Recruiting
Phase 2

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.120 enrolled1 locationNCT07028281
Recruiting
Phase 2

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Malignant Solid Tumors
M.D. Anderson Cancer Center40 enrolled1 locationNCT06629584
Recruiting
Phase 2

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.400 enrolled2 locationsNCT07268040
Recruiting
Phase 1Phase 2

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.300 enrolled1 locationNCT06737731
Recruiting
Phase 1

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
Xingchen Peng6 enrolled1 locationNCT07100210
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech340 enrolled2 locationsNCT06115642
Recruiting
Not Applicable

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Malignant Solid Tumors
Memorial Sloan Kettering Cancer Center109 enrolled2 locationsNCT02421380
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Mesothelin-Expressing TumorsEpithelial Ovarian CancerLung Adenocarcinoma Metastatic+7 more
Context Therapeutics Inc.70 enrolled8 locationsNCT06756035
Recruiting
Not Applicable

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University24 enrolled1 locationNCT07010523
Recruiting
Phase 1

MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors

B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
Zhejiang University12 enrolled1 locationNCT06912152
Recruiting
Not Applicable

The Effect of Serum Ferritin in irAE

Acute LeukemiaMalignant Solid TumorsImmune-related Adverse Event+1 more
Tianjin Medical University Cancer Institute and Hospital1,500 enrolled1 locationNCT06702566
Recruiting
Phase 1

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

CDH17-positive Advanced Malignant Solid Tumors
Shanghai Pudong Hospital17 enrolled1 locationNCT06501183
Recruiting
Early Phase 1

Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors

Malignant Solid Tumors
Peking University Cancer Hospital & Institute24 enrolled1 locationNCT05579275
Recruiting

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Soft Tissue SarcomaMelanomaMalignant Solid Tumors+1 more
N.N. Petrov National Medical Research Center of Oncology1,000 enrolled1 locationNCT05539677